Tiziana Life Sciences reports qualitative improvement in MS patients treated with lead asset
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled encouraing results from patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) enrolled in its Expanded Access Program who have been receiving its drug asset foralumab for at least six months. The company is developing foralumab, the only fully human anti-CD3 mAb, which has demonstrated a favorable safety profile and clinical response in patients in studies to date.
Tiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it along with its research partners at Mass General Hospital have been invited to apply for a prestigious grant from the ALS Association to fund a clinical trial evaluating its asset intranasal foralumab. The company said the grant is offered as part of the Hoffman ALS Clinical Trial Awards Program, which helps develop new and improved therapies for ALS by supporting early-stage clinical trials.
Tiziana Life Sciences' chief advisor to receive "Giants of MS" award
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2024, during the Consortium of Multiple Sclerosis Centers annual meeting in Nashville, Tennessee.
